ViroPharma Inc. recently received 'orphan drug designation' in the EU for its pipeline candidate, maribavir, for the treatment of cytomegaloviral in patients suffering from impaired cell mediated immunity.
http://www.investopedia.com/stock-analysis/zacks/061213/orphan-drug-status-viropharmas-maribavir-analyst-blog-vphm-rhhby-gsk-slxp.aspx?partner=rss_headlines
http://www.investopedia.com/stock-analysis/zacks/061213/orphan-drug-status-viropharmas-maribavir-analyst-blog-vphm-rhhby-gsk-slxp.aspx?partner=rss_headlines
No comments:
Post a Comment